https://doi.org/10.4081/hmr.v3i1.525

Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 247
PDF: 321
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Duvic
support@pagepress.org
Deacetylases (DACs) belong to one of three highly conserved classes of 18+ known enzymes whose functions are to remove acetyl groups from various proteins, including DNA associated histones (HDACs). Histone acetylases are enzymes that acetylate proteins and have been found to be mutated in cancer cells. The balance between acetylation (mediated by HATs) and deacetylation (mediated by HDACs) controls gene transcription and imbalance can lead to malignant transformation. Although HDACs are known for their abilities to acetylation the DNA associated histone proteins, DACs actually predate histones and are highly conserved proteins. DACs acetylate a large number of other proteins, including tumors suppressors (p53, p21). Acetylation and methylation are called epigenetic variations of DNA and are important signaling devices for transcription factors. Manipulating gene transcription by epigenetic mechanisms, including demethylation and acetylation, is a novel approach for the treatment of cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Duvic, M. (2009). Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.525
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).